ECO 2026: Indirect Comparison Favors Wegovy Pill Over Foundayo

At the 33rd European Congress on Obesity in Istanbul, Novo Nordisk presented findings from a post-hoc indirect treatment comparison between two oral GLP-1 receptor agonists approved for weight management in the US: Wegovy (oral semaglutide) and Foundayo (orforglipron). Due to the absence of head-to-head trials, researchers used data from the Phase III OASIS-4 and ATTAIN-1 trials, employing simulated treatment comparison and matching-adjusted indirect comparison methods to align patient populations. The analysis revealed that oral semaglutide demonstrated superior efficacy, with mean weight reduction exceeding orforglipron by approximately 3.0 to 3.2 percentage points. Furthermore, tolerability outcomes significantly favored Wegovy, as orforglipron was associated with a markedly higher risk of discontinuation due to adverse events and gastrointestinal issues. While key opinion leaders noted Wegovy's administration requirements as a potential disadvantage compared to orforglipron, the study highlights Wegovy's advantages in both efficacy and safety profile. These results are expected to influence clinical positioning and health technology assessments as competition in the oral obesity treatment market intensifies, with numerous candidates currently in development globally.